SMAD4 is also mutated or deleted in 10%–15% and 20%–50% of colorectal and pancreatic cancers, respectively (10–12), in which its loss of expression is associated with inferior outcomes in patients with colorectal cancer (13–15) and pancreatic cancer (16–18). This evidence concerns the gene SMAD4 and colorectal cancer.